Due to the role of estrogen in breast cancer, aromatase inhibitors (inhibitors of the estrogen-metabolizing enzyme aromatase) are used in the treatment of postmenopausal individuals with ER-positive breast cancer, despite problems with bone fractures. Here, CYP19A1 is linked to breast carcinoma.